Replies to post #6433 on Intellect Neurosciences Inc. (fka ILNS)

[streetsmartstocks]

Well said Johnny, well said.

[Johnny4profits]

ILNS is on my HOT TO STALK list!

I think that it is great
when we have street smart people whom have different opinions to share as we all see different things in the information provided and sometimes find links and resources others have missed. I look forward to sharing sentiments in regards to ILNS as I am quite convinced that Intellect Neurosciences is doing all the right things to position themselves for a reversal with negative cash flow and a successful PPS future. It takes all kinds of opinions and intellect to make a successful stock and company. Lockstep on the streets is never healthy.

I think that before I buy into ILNS that I would want to see the share structure. I decided to go searching for this information as it appears to my street smartness that it may be key to understanding some important fundamentals about the company and who knows what may turn up. First I looked at the latest OTC filings and post some of it here for those whom have not looked themselves: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8613876

Operating loss increased $534,475 to a loss of $952,650 for the three months ended March 31, 2012 from a loss of $418,175 for the three months ended March 31, 2011. This was due to an increase in both our Research and Development costs as well as an increase in General and Administrative expenses.

Other expenses decreased by $1,936,027, to expense of $6,000,394 for the three months ended March 31, 2012, from expense of $7,936,421 for the three months ended March 31, 2011. The decrease was due to a decrease in the change in the value of derivative instruments and preferred stock liability of $1,054,721, and a decrease in interest expense of $881,306 due to the interest that was recorded at the issuance of the March 2011 Notes.

Research and Development costs increased by $4,964, from $28,384 for the three months ended March 31, 2011 to $33,348 for the three months ended March 31, 2012, primarily due to increased R&D activities with respect to our clinical drug candidate, OX1.

General and Administrative expenses increased by $529,511 to $919,302 for the three months ended March 31, 2012, from $389,791 for the three months ended March 31, 2011. The increase in General and Administrative expenses was primarily due to a large increase in professional fees, primarily legal patent fees as well as small increases in various other accounts..

Oh my, I just don't find the cut and dry share structure in this last reporting. I get the 2,000,000,000 A/S, but don't clearly see the rest, such as O/S and FLOAT. I get lost in all the warrants and issueings and can't retire on crunching the numbers here. Maybe I just overlooked it or something. I'll go out and find the TA and someone whom can provide this information. If anyone has this updated share structure and is willing to share it, I'd sure appreciate receiving that information.

Oh, and the iBox link http://biz.yahoo.com/e/111013/ilns.pk10-k.html has evidently expired.

NOTE, RUSHING POST HERE: FOUND RS APRIL 4TH, 2011. MADE ERROR IN LOOKING FOR IT ON 2012. APOLOGIES FOR ERROR.

The other one, http://ir.stockpr.com/intellectns/press-releases/detail/493/intellect-neurosciences-initiates-capital-markets-plan , dated April 8, 2011 announces: "the Company's stockholders approved, by way of written consent, a one-for-fifty (1 for 50) reverse stock-split of the Company's outstanding shares of common stock to take effect on April 12, 2011. The reverse split will not affect the number of authorized shares of the Company's common stock, which will remain at a total of two billion shares. Today's announcement follows successive important developments that were achieved with respect to Intellect's product pipeline, technology platforms and patent portfolio." But I don't see that the RS has happened yet and that suggests to me that it is still hanging over our heads! Lots of reading to do here. Things are not quite so clear for anyone merely meandering down the street.

My bottom line at this moment is that I will continue to look carefully at ILNS and will refrain from being caught up in some promoting play with the stock while reality may not support that PPS increase. I am certainly for the product development and the success of the business platform, but we all know that this world of medical and drug research is a long arduous task with many investor risks. Eventually, if everything succeeds, everyone in play following any number of RS actions and having bought in low will make big jingle. That is certainly something making it worth while to watch and study and not ignore an excellent play such as ILNS. I'm just beginning my DUH DUH.


BE SURE TO HIT YOUR "FOLLOW BOARD" IN SUPPORT OF YOUR ILNS STOCK INTERESTS.
http://www.otcmarkets.com/stock/ILNS/quote
http://www.intellectns.com/
#138 ON FOLLOWERS!
NOTE: ILNS IMO is just that, IMO, and is not intended as
investment advice. This is adult sport and everyone is
responsible for their own decisions, profits and loses.
.